Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.
Splenic lymphoma with villous lymphocytes (SLVL) is a B-cell chronic lymphoproliferative disorder. Splenectomy and/or chlorambucil (CLB) are usually regarded as the most effective treatment in SLVL patients. However, a few patients relapse and the second line therapy remains questionable. Although 2-Cda has been evaluated in patients with chronic lymphoid leukemia (CLL) and hairy cell leukemia (HCL), it has been reported as the treatment of SLVL in only one case report. Therefore, we have evaluated its efficacy and toxicity in 7 SLVL patients. The median duration between diagnosis and treatment was 18 months (range, 1 to 59). The patients received 2-CdA (0.1 mg/kg/d) by venous infusion for 7 days with a median number of 1 cycle (range, 1 to 2) either as a first line therapy (one patient) or after a failure of other therapies (splenectomy, chemotherapy). Two patients achieved a complete response. The first one maintained his CR during a follow-up of 9 months and then relapsed; the second patient remained in CR after a follow-up of 20 months. Four patients achieved a partial response and relapsed after a median follow-up of 3.5 months (range, 1 to 4). One patient had no response. The treatment was not well tolerated with many infectious events. In the limits of our study, 2-Cda does not appear to be efficient therapy for SLVL and is not well tolerated for patients in relapse after splenectomy or resistant to CLB.
Lefrère
F
F
Service d'Hématologie Adultes, Hĵpital Necker, Paris, France.
Hermine
O
O
François
S
S
Panelatti
G
G
Valensi
F
F
Grosbois
B
B
Misset
J L
JL
Varet
B
B
Troussard
X
X
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000592:standards / Q000633:toxicity; D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000592:standards / Q000633:toxicity; D017338:Cladribine / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000592:standards / Q000633:toxicity; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013160:Splenic Neoplasms / Q000188:drug therapy*; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C097601:cladribine triphosphate; D017338:Cladribine; D000255:Adenosine Triphosphate